Literature DB >> 17035751

Specific therapies for human papilloma virus infections.

R Snoeck1, G Andrei, E De Clercq.   

Abstract

Human papillomavirus induces the hyperproliferation of epithelial cells, leading to a broad spectrum of human diseases, ranging from benign warts to malignant neoplasms, depending on the location of the lesion, the immune status of the patient and the type of human papillomavirus. Current therapies for human papillomavirus-associated diseases are based on the excision or ablation of dysplastic or malignant tissue, and are associated with a high frequency of recurrent disease, discomfort and costs. A better understanding of the viral replicative cycle and of the interaction between the virus and the host cell, particularly the cell cycle regulation, has opened new perspectives. Recently, new treatment modalities for human papillomavirus-induced lesions have been identified, including the use of antiviral/immunomodulatory therapies, such as cidofovir, antisense oligonucleotides, imiquimod and human papillomavirus vaccines.

Entities:  

Year:  1998        PMID: 17035751     DOI: 10.1097/00001432-199812000-00014

Source DB:  PubMed          Journal:  Curr Opin Infect Dis        ISSN: 0951-7375            Impact factor:   4.915


  5 in total

1.  Xenograft model for identifying chemotherapeutic agents against papillomaviruses.

Authors:  A Pawellek; G Hewlett; J Kreuter; H Rübsamen-Waigmann; O Weber
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

2.  Safety of intralesional cidofovir in patients with recurrent respiratory papillomatosis: an international retrospective study on 635 RRP patients.

Authors:  R E A Tjon Pian Gi; T Ilmarinen; E R van den Heuvel; L M Aaltonen; J Andersen; J W Brunings; M Chirila; A Dietz; F Ferran Vilà; G Friedrich; H H W de Gier; W Golusinski; M Graupp; A Hantzakos; R Horcasitas; J Jackowska; J C Koelmel; G Lawson; F Lindner; M Remacle; C Sittel; V Weichbold; M Wierzbicka; F G Dikkers
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-02-03       Impact factor: 2.503

3.  Treatment of recurrent respiratory papillomatosis and adverse reactions following off-label use of cidofovir (Vistide®).

Authors:  Robin E A Tjon Pian Gi; Andreas Dietz; Vojko Djukic; Hans E Eckel; Gerhard Friedrich; Wojciech Golusinski; Anastasios Hantzakos; George Lawson; Marc Remacle; Heikki Rihkanen; Frederik G Dikkers
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-10-22       Impact factor: 2.503

Review 4.  Pathologies of the larynx and trachea in childhood.

Authors:  Christian Sittel
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2014-12-01

5.  Resistance to the nucleotide analogue cidofovir in HPV(+) cells: a multifactorial process involving UMP/CMP kinase 1.

Authors:  Dimitri Topalis; Tatiane C Nogueira; Tim De Schutter; Chahrazade El Amri; Marcela Krečmerová; Lieve Naesens; Jan Balzarini; Graciela Andrei; Robert Snoeck
Journal:  Oncotarget       Date:  2016-03-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.